Kura Oncology gains as FDA accepts marketing application for blood cancer drug
View all comments(0)
Kura Oncology KURA.O shares jump 14% to $6.49 in pre-market trading
KURA and Japan-based Kyowa Kirin 4151.T say the US FDA accepted marketing application for ziftomenib
The drug, if approved, could be used to treat patients with acute myeloid leukemia, a type of blood cancer
The disease affects about 22,000 people in the US every year, according to American Cancer Society
Ziftomenib is a potential first-of-its-kind treatment for this aggressive form of leukemia, the cos say
The FDA has granted priority review and is likely to decide by November 30 this year, they added
YTD, stock down 34.7%, as of last close
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
'Big Short' Burry Doubles Down: Nvidia, Palantir Short Positions Double in Big Bet on AI Bubble Bursting

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

U.S. April CPI Preview: Fed May Abandon Rate Cuts Until 2026?

Rocket Lab Earnings Greatly Exceed Expectations, Ignoring Risks as Stock Price Surges?

Tradingkey






Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.